PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Status Terminated

Clinical Trial Summary

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Richter's Transformation

Clinical Trial Details

NCT number	NCT02378038
Study type	Interventional
Source	Sierra Oncology LLC - a GSK company
Contact
Status	Terminated
Phase	Phase 2
Start date	August 2015
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02138786` - Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation	Phase 2
Terminated	`NCT03153514` - Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation	Phase 2
Completed	`NCT00472849` - Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias	Phase 1/Phase 2
Recruiting	`NCT05294731` - Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader	Phase 1/Phase 2
Active, not recruiting	`NCT03162536` - A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)	Phase 1/Phase 2
Terminated	`NCT03121534` - Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation	Phase 2
Recruiting	`NCT06043674` - A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation	Phase 2
Completed	`NCT01217749` - Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL	Phase 1/Phase 2
Recruiting	`NCT04305444` - Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas	Phase 2
Active, not recruiting	`NCT04806035` - Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Phase 1
Terminated	`NCT03778073` - Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma	Phase 1